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Signaling through G proteins normally involves
conformational switching between GTP- and GDP-
bound states. Several Rho GTPases are also regu-
lated by RhoGDI binding and sequestering in the
cytosol. Rnd proteins are atypical constitutively
GTP-bound Rho proteins, whose regulation remains
elusive. Here, we report a high-affinity 14-3-3-bind-
ing site at the C terminus of Rnd3 consisting of
both the Cys241-farnesyl moiety and a Rho-associ-
ated coiled coil containing protein kinase (ROCK)-
dependent Ser240 phosphorylation site. 14-3-3
binding to Rnd3 also involves phosphorylation of
Ser218 by ROCK and/or Ser210 by protein kinase
C (PKC). The crystal structure of a phosphorylated,
farnesylated Rnd3 peptide with 14-3-3 reveals a
hydrophobic groove in 14-3-3 proteins accommo-
dating the farnesyl moiety. Functionally, 14-3-3
inhibits Rnd3-induced cell rounding by translocat-
ing it from the plasma membrane to the cytosol.
Rnd1, Rnd2, and geranylgeranylated Rap1A interact
similarly with 14-3-3. In contrast to the canonical
GTP/GDP switch that regulates most Ras super-
family members, our results reveal an unprece-
dented mechanism for G protein inhibition by
14-3-3 proteins.640 Cell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. Open access unINTRODUCTION
Most Ras superfamily G proteins cycle between an inactive
GDP-bound conformation and an active GTP-bound conforma-
tion, which signals to downstream targets to induce cellular re-
sponses. They are activated by guanine nucleotide exchange
factors (GEFs) and inactivated by GTPase activating proteins
(GAPs), which catalyze GTP hydrolysis. The three Rnd proteins,
Rnd1, Rnd2, and Rnd3 (also known as RhoE) are a subfamily of
the Rho GTPase family with atypical properties (Foster et al.,
1996; Riou et al., 2010). They are constitutively GTP-bound
because they have amino acid substitutions in key residues
involved in GTP hydrolysis, and have a very low affinity for
GDP. Their activity must therefore be regulated differently to
classic G proteins (Riou et al., 2010). For Rnd3, one such mech-
anism is phosphorylation by Rho-associated coiled coil contain-
ing protein kinase (ROCK)1 and protein kinase C (PKC)a, which
shifts Rnd3 subcellular localization from the plasma membrane
to the cytoplasm and increases its stability (Madigan et al.,
2009; Riento et al., 2005). The molecular basis for these effects
remains uncharacterized. Rnd2 localizes predominantly to the
cytoplasm, whereas Rnd1 is normally localized on membranes
(Roberts et al., 2008). Whether the localization of Rnd1 and
Rnd2 is also regulated by phosphorylation is not known.
Like most Ras superfamily G proteins, Rnd proteins are post-
translationally polyisoprenylated on a Cys residue, four amino
acids from the C terminus (Cys of the CAAX box motif, where
C represents cysteine; A an aliphatic amino acid; and X any
amino acid residue, which determines the type of isoprenyl
   der CC BY license.
 group). Isoprenylation is followed by proteolytic removal of the
AAX amino acids and carboxymethylation of the polyisoprenyl-
cysteine. These irreversible modifications mediate the interac-
tion of the GTPases with membranes and are generally required
for their biological functions. Basic residues near the C terminus
of some GTPases such as Rac1 and K-Ras4B also contribute to
their membrane localization (Hancock et al., 1990; Michaelson
et al., 2001; van Hennik et al., 2003). The Rho GTPases RhoA,
Rac1, and Cdc42 are posttranslationally modified by a 20-car-
bon geranylgeranyl lipid and are solubilized from membranes
and sequestered in the cytosol in an inactive state by binding
to RhoGDIs, which have a hydrophobic pocket that accommo-
dates the geranylgeranyl group (Hoffman et al., 2000). In
contrast, Rnd proteins are modified by a shorter 15-carbon far-
nesyl group (Foster et al., 1996; Roberts et al., 2008), and
Rnd3 does not bind and therefore is not extracted from mem-
branes by RhoGDIs (Forget et al., 2002). This implies the exis-
tence of an alternative mechanism for the Rnd proteins to
localize in the cytosol.
Rnd1 and Rnd3 induce loss of stress fibers and cell rounding
(hence the name Rnd) in a variety of cell types and can stimulate
cell migration (Riou et al., 2010). One way in which Rnd proteins
regulate cell morphology is by inhibiting the Rho/ROCK signaling
pathway and hence antagonizing actomyosin contractility. Over-
expression of Rnd1 and Rnd3 stimulates p190RhoGAP activity,
which reduces the amount of GTP-bound RhoA and decreases
stress fibers (Wennerberg et al., 2003). Rnd3 also inhibits acto-
myosin contractility at cell-cell contacts in epithelial cells during
collective cell migration (Hidalgo-Carcedo et al., 2011).
Here, we identify 14-3-3 proteins as Rnd interaction partners.
14-3-3 proteins are regulatory molecules that bind many func-
tionally diverse proteins, usually by interacting with Ser/Thr
phosphorylated residues (Obsil and Obsilova, 2011). We show
that 14-3-3 binds Rnd proteins through a phosphorylated Ser
residue and the adjacent C-terminal farnesyl group. By solving
the crystal structure of a C-terminal Rnd3 peptide/14-3-3 com-
plex, we show that 14-3-3 proteins directly interact with the far-
nesyl group via a hydrophobic surface, revealing lipid binding to
14-3-3. Using a consensus motif based on the Rnd3 C-terminal
sequence, we identify several proteins with potential to bind to
14-3-3 in a similar fashion to Rnd3 and show that among them
geranylgeranylated Rap1A interacts with 14-3-3. Therefore, 14-
3-3 proteins can act as solubilizing factors specifically for phos-
phorylated and prenylated proteins from the Ras superfamily,
translocating them from their site-of-action—on membranes—
to the cytosol and consequently inhibiting their function.
RESULTS
Rnd3 Interacts with 14-3-3 Proteins via C-Terminal
Phosphorylation Sites
Rnd3 was identified in immunoprecipitates of 14-3-3ε (Michael
Yaffe, personal communication), and four endogenous 14-3-3
isoforms (b, ε, g, z) were identified as Rnd3-binding partners by
mass spectrometry analysis (Table S1 available online). This is
the first time a Ras superfamily G protein has been reported to
bind to 14-3-3 proteins. Seven 14-3-3 isoforms are known in
mammals (Morrison, 2009), and because all isoforms coimmu-Open access under CC noprecipitated with Rnd3 (Figure S1A), no isoform specificity
was observed.
In most cases, 14-3-3 proteins interact with phosphorylated
Ser/Thr residues on their target proteins (Morrison, 2009). Treat-
ment of cells with the general kinase inhibitor staurosporine
reduced Rnd3/14-3-3 interaction, and conversely the phospha-
tase inhibitor calyculin A increased the interaction (Figure S1B).
In addition, treatment of Rnd3 immunoprecipitates with calf-
intestinal phosphatase to dephosphorylate Rnd3 abolished
subsequent interaction with 14-3-3 proteins (Figure 1A). Rnd3
phosphorylation is therefore required for binding to 14-3-3.
Previously, we identified seven Ser/Thr residues in Rnd3 that
can be phosphorylated in vitro by ROCK1, two near the N termi-
nus and five near the C terminus (Riento et al., 2005; Figure 1B).
PKC also phosphorylates Rnd3 on one or more of these sites
(Madigan et al., 2009). Mutation of all seven sites to Ala (Rnd3-
AllA; Figure 1B) prevented Rnd3 from binding to recombinant
GST-14-3-3b in vitro or endogenous 14-3-3 proteins in cells (Fig-
ures S1C and S1E), indicating that at least one of these residues
is involved in the interaction. Deletion of the Rnd3C terminus, but
not the N terminus, abolished 14-3-3 interaction (Figures S1D
and S1E), implicating C-terminal residues specifically. To map
which Rnd3 phosphorylation site(s) mediate 14-3-3 interaction,
each Ser/Thr was individually mutated to Ala. Mutation of Rnd3
S240 alone totally prevented the interactionwith 14-3-3 proteins,
whereas mutation of either S210 or S218 reduced the interaction
(Figure 1C). A putative phosphomimetic mutant, Rnd3-S240D,
did not bind 14-3-3 proteins (Figure 1D), in accordance with pre-
vious studies showing that 14-3-3 proteins require phosphate
groups and not simply negatively charged amino acid side
chains for binding (Muslin et al., 1996; Obsil and Obsilova, 2011).
To determine whether any single phosphorylation site(s) was
sufficient for 14-3-3 binding, each of the phosphorylation sites
was reintroduced individually or in combination into the Rnd3-
AllA background. Of these Rnd3 mutants, only Rnd3-AllA-
S210+S240 and Rnd3-AllA-S218+S240 could interact similarly
to wild-type (WT) Rnd3 (Figure 1E; data not shown), whereas
Rnd3-AllA-S240 displayed a weak interaction with 14-3-3 pro-
teins (Figure S1F). Taken together, this indicates that S240 phos-
phorylation is essential for interaction with 14-3-3 proteins and
that either S210 or S218 phosphorylation is also required in com-
bination with S240 for optimal binding. These three phosphory-
lation sites and surrounding amino acids are completely
conserved in Rnd3 proteins from a range of species (Figure S1G;
note that Rnd3 is only present in vertebrates [Boureux et al.,
2007]), providing strong evidence that they play an important
role in Rnd3 function.
C-Terminal Phosphorylation of Rnd3 by ROCK1 and PKC
Leads to 14-3-3 Interaction
Both ROCK1 (but not ROCK2) and PKC are reported to
phosphorylate Rnd3, although the site(s) phosphorylated by
PKC have not been identified (Madigan et al., 2009; Riento
et al., 2005). To determine which sites were phosphorylated
by ROCK1 or PKC, Rnd3 phosphosite mutants were expressed
in COS7 cells, and immunoprecipitated Rnd3 was incubated
with ROCK1 kinase domain or PKCz kinase domain (Fig-
ure 2A). ROCK1 phosphorylated each of the seven Ser/ThrCell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. 641
 BY license.
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Figure 1. Rnd3 Binds to 14-3-3 Proteins via C-Terminal Phosphorylation Sites
(A) Expression vectors encoding FLAG-Rnd3 and HA-14-3-3 isoforms were transfected into COS7 cells. Cell lysates were immunoprecipitated (IP) with FLAG
antibody, then treated with or without CIP for 1 hr. Immunoprecipitates were then incubated with cell lysates containing HA-14-3-3 proteins and immunoblotted
(IB) with antibodies against FLAG and HA.
(B) Schematic showing 7 Rnd3 phosphorylation sites (S/T), mutated to A in AllA.
(C–E) The indicated FLAG-Rnd3 mutants were transfected into COS7 cells. Cells were lysed and immunoprecipitated with FLAG antibody. Endogenous 14-3-3
proteins bound to FLAG-Rnd3 were detected with 14-3-3 antibody. In (D), the space in the gel image marks the position of lanes that were not germane to these
results and were thus removed during figure preparation for clarity.
Asterisk (*) indicates IgG light chain; S: Serine, T: Threonine, A: Alanine. See also Figure S1 and Table S1.phosphorylation sites but S210 had a much lower level of phos-
phorylation than the other six sites. In contrast, only S210 was
effectively phosphorylated by PKCz. Hence, of the Rnd3 resi-
dues involved in 14-3-3 binding, S210 is a target for PKC,
whereas both S218 and S240 are ROCK targets (Figure 2A).
Note that PKC kinase domains have overlapping substrate
specificity in vitro (Nishikawa et al., 1997), and S210 could
potentially be phosphorylated by any PKC isoform, although
PKCa seems to be the predominant isoform acting on Rnd3
in PMA-stimulated fibroblasts (Madigan et al., 2009). Interest-
ingly, mutation of Ser240 to Thr did not affect 14-3-3 binding
(Figure 1D), indicating that ROCK1 is likely to phosphorylate
either Ser or Thr residues equally efficiently at this position.
To investigate the phosphorylation status of the three Rnd3
phosphorylation sites involved in 14-3-3 binding in cells, we first642 Cell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. Open access ungenerated an antibody specific to pSer210 of Rnd3. Treatment of
cells with PMA but not overexpression of ROCK11–420 stimulated
an increase in pS210-Rnd3 and binding to 14-3-3, whereas the
PKC inhibitor BIM1 reduced pS210-Rnd3, indicating that S210
is a PKC phosphorylation site in cells (Figure 2B). This antibody
did not recognize other phosphorylation sites in Rnd3 (Figure 2C;
data not shown). Mass spectrometry analysis of immunoprecip-
itated FLAG-Rnd3 was used to show that S218 and S240 were
phosphorylated in cells expressing ROCK11–420 or treated with
calyculin A (Figures S2A and S2B). Because S240 is adjacent
to C241, which is normally farnesylated and methylated, we
developed a methodology using synthetic peptides as refer-
ences in order to be able to identify C-terminal modifications
on Rnd3 immunoprecipitated from cell lysates. Rnd3-pS240
was specifically detected in a farnesylated, methylated peptide der CC BY license.
(Figure S2B). As a control, clear identification of the farnesylated
but not phosphorylated, C-terminal sequence was obtained for
Rnd3-S240A (data not shown).
We also monitored Rnd3 phosphorylation in parallel to 14-3-3
binding using a pSer antibody raised against PKC substrate
consensus sequences. Inhibition of PKC or ROCK decreased
levels of Rnd3 phosphorylation detected with this pSer antibody,
whereas in cells expressing constitutively active ROCK11–420 or
stimulated with PMA, the levels increased (Figure 2B). This
indicates that the antibody recognizes both ROCK1 and PKC
phosphosites. Indeed, PKCs and ROCKs are both from the
AGC family of kinases and have very similar consensus phos-
phorylation sites (Pearce et al., 2010). The pSer antibody binding
to Rnd3 was strongly reduced by mutation of S210, S218, or
S240, and similar to wild-type Rnd3 for the AllA-S210, S218,
S240 mutant (Figure 2C), indicating that these are the major
phosphosites that it recognizes. Similar results were observed
using the Pro-Q Diamond reagent to measure Rnd3 phosphory-
lation (see Extended Experimental Procedures) (Figures 2B and
2C). These results together demonstrate for the first time that
Rnd3 is phosphorylated in cells on S210 by PKC and on S218
and S240 by ROCK, leading to 14-3-3 binding (Figure S2C).
Rnd1 and Rnd2 Are Phosphorylated and Interact with
14-3-3 Proteins
Unlike Rnd3, phosphorylation of Rnd1 and Rnd2 has not been
reported. Both Rnd1 and Rnd2 possess a Ser residue equivalent
to Rnd3-S240 next to the CAAX box, as well as several other po-
tential phosphorylation sites close to the C terminus (Figure 2D).
These sites, however, are not conserved between the Rnd iso-
forms. We detected phosphorylation of Rnd1 and Rnd2 in cells,
which was increased following addition of phosphatase inhibitor
(calyculin A) to cells prior to lysis (Figure 2E). Under these condi-
tions, and correlating with their level of phosphorylation, Rnd1
and Rnd2 were able to interact with 14-3-3 proteins (Figure 2E).
Mutation of S228 in Rnd1 and S223 in Rnd2, both next to the
CAAX box (Figure 2D), prevented 14-3-3 binding (Figure 2F).
This suggests that Rnd1 and Rnd2 are regulated similarly to
Rnd3 by C-terminal phosphorylation and 14-3-3 binding.
14-3-3 Binding Inhibits Rnd3 Function by Inducing Its
Translocation from thePlasmaMembrane to theCytosol
Exogenous expression of Rnd3 typically induces cell rounding
with long thin protrusions due to inhibition of Rho activity and
subsequent loss of stress fibers and focal adhesions (Guasch
et al., 1998; Nobes et al., 1998). This response is mediated
in part by the interaction of Rnd3 with p190RhoGAP and
stimulation of its GAP activity toward RhoA (Wennerberg et al.,
2003). The Rnd3/14-3-3 interaction is not necessary for Rnd3-
induced cell rounding because Rnd3-AllA, and other Rnd3 mu-
tants defective in their ability to bind 14-3-3 proteins, induced
a similar rounding response to wild-type Rnd3 in NIH 3T3 fibro-
blasts (Figure S3A). Both wild-type and Rnd3 phosphomutants
localized to the plasma membrane in all cells with a rounded
phenotype.
Rnd3-AllA coimmunoprecipitated with p190RhoGAP-B,
similar to WT Rnd3 (Figure S3B), and thus 14-3-3 binding is
not required for this interaction. As a control, Rnd3-T55V didOpen access under CC Bnot interact with p190RhoGAP-B (Figure S3B), consistent with
previous data (Pacary et al., 2011; Wennerberg et al., 2003).
Interestingly, Rnd3/14-3-3 and Rnd3/p190RhoGAP-B were in
two mutually exclusive complexes: immunoprecipitates of
p190RhoGAP-B contained Rnd3 but not 14-3-3 proteins, and
conversely immunoprecipitates of 14-3-3 proteins contained
Rnd3 but not p190RhoGAP-B (Figure S3C). In addition, Rnd3
bound to 14-3-3 proteins was phosphorylated on S210, whereas
Rnd3 bound to p190RhoGAP-B was not (Figure S3C). This sug-
gests that phosphorylation of Rnd3 increases its interaction with
14-3-3 proteins and reduces interaction with the effector
p190RhoGAP.
We next investigated whether 14-3-3 binding inhibited Rnd3
function. As described above, Rnd3 and Rnd3-A240 both
induced loss of stress fibers and cell rounding (Figures 3A, and
S3A). Coexpression of 14-3-3b significantly inhibited the round-
ing response induced by wild-type Rnd3, but not Rnd3-A240,
whereas 14-3-3b expression alone did not alter cell morphology
(Figures 3A, 3B, andS3D; TableS2). By contrast, amutant 14-3-3
protein that is defective for substrate binding (Thorson et al.,
1998) did not inhibit Rnd3-induced cell rounding (data not
shown). This provides evidence that the effect of 14-3-3b on
cell morphology is specific to binding and inhibition of Rnd3
and not due to binding to another cellular target. Because 14-3-
3 proteins bind to the C-terminal region of Rnd3 close to the far-
nesylation site (Figure S2C), we hypothesized that 14-3-3 binding
could affect Rnd3 subcellular localization and consequently
negatively regulateRnd3 function. Indeed, as observed by immu-
nofluorescence, 14-3-3b overexpression dramatically reduced
the localization of Rnd3 but not Rnd3-A240 at the plasma mem-
brane (Figure 3B). Importantly, the rounding response to WT
Rnd3 and Rnd3-S240A correlated with Rnd3 localization at the
plasma membrane (Figures 3B, S3A, and S3E). Similar to Rnd3,
14-3-3 overexpression inhibited Rnd1- and Rnd2-induced
morphological changes, indicating that the function of all 3 Rnd
proteins can be inhibited by 14-3-3 interaction (Figure S3F).
To confirm the effect of 14-3-3 proteins on Rnd3 localization,
we investigated Rnd3 association with membranes by
biochemical fractionation. Rnd3 was equally distributed be-
tween the cytosolic and membrane fractions but absent from
the nuclear fraction. Coexpression of 14-3-3b and/or ROCK1
increased the proportion of Rnd3 in the cytosolic fraction,
concomitant with reduced levels of Rnd3 in the membrane frac-
tion (Figure 3C, upper left). In contrast, Rnd3-S240A localization
was unaffected by ROCK1 or 14-3-3b expression (Figure 3C, up-
per right). 14-3-3 proteins localized to all fractions (Figure 3C,
lower), as expected given their large number of cellular partners
(Morrison, 2009). As a control, a Rnd3-C241S mutant was
tested. C241 is the site of farnesyl group addition to Rnd3 (Fig-
ure S2C). Rnd3-C241S could not bind to membranes and local-
ized only in the cytosolic fraction, as expected (Figure 3C, lower).
Additional controls using PMA or calyculin A to increase Rnd3
phosphorylation or staurosporine to reduce phosphorylation
showed that unphosphorylated Rnd3 mainly localizes to the
membrane fraction, whereas phosphorylated Rnd3 accumulates
in the cytosol (Figure 3C, lower panels). In addition, pS210-Rnd3
localized only in the cytosolic fraction and not the membrane
fraction (Figure S3G), supporting our data indicating that Rnd3Cell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. 643 Y license.
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Figure 2. Rnd3 C-Terminal Phosphorylation by ROCK and PKC Is Required for 14-3-3 Interaction
(A–C) The indicated constructs were transfected into COS7 cells. Cell lysates were immunoprecipitated with FLAG antibody. (A) Immunoprecipitates were
subjected to an in vitro kinase assay with either ROCK1 or PKCz kinase domains. (B) FLAG-Rnd3 was co-overexpressed with ROCK11–420 where indicated.
Cells were treated with chemical inhibitors (staurosporine, calyculin A, H-1152 [ROCK], BIM1 [PKC]) or the chemical activator PMA (PKC) for 2 hr (20 min
for calyculin A) prior to lysis. Cell lysates were stained with Pro-Q Diamond reagent or immunoblotted with the indicated antibodies. The space in the
gel image marks the position of lanes that were not germane to these results and were thus removed during figure preparation for clarity. (C) Endogenous
14-3-3 proteins were detected with anti-14-3-3 antibody. Membranes were also stained with Pro-Q Diamond reagent or immunoblotted with the indicated
antibodies.
(legend continued on next page)
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phosphorylation induces translocation from the membrane to
the cytosol through 14-3-3 binding.
Taken together, these results indicate that plasmamembrane-
localized Rnd3 is active, binds p190RhoGAP and induces cell
rounding and thin protrusions, whereas upon phosphorylation
followed by subsequent 14-3-3 binding, it translocates to the
cytosol where it is inactive and cannot alter cell morphology.
Rnd Farnesylation Is Required for 14-3-3 Interaction
The proximity of Rnd3 pS240 to farnesylated C241 (Figure S2C)
led us to investigate the influence of farnesylation on 14-3-3
binding. We therefore mutated C241 to either G or S, or deleted
the last four amino acids (Rnd3DCAAX), thus preventing Rnd3
farnesylation. Strikingly, none of the three CAAX box mutants in-
teracted with 14-3-3 proteins (Figure 4A). Rnd3-C241S did not
localize to the plasma membrane but in the cytoplasm and
nucleus (Figures S4A and 3C), as expected in the absence of
farnesylation (Roberts et al., 2008). Rnd3DC, which lacks the
C-terminal phosphorylation sites and theCAAXbox (Figure S1D),
as expected, did not bind to 14-3-3 proteins (Figure 4A). Addition
of a CAAX box to Rnd3DC did not restore 14-3-3 protein binding
(Figure 4A), which is consistent with the requirement for the Rnd3
C-terminal phosphorylation sites for 14-3-3 interaction (Figures 1
and 2). As the interaction between Rnd3 and 14-3-3 proteins re-
quires Rnd3 phosphorylation, the above data could be explained
by the fact that Rnd3 needs to be at the plasma membrane,
where it can be phosphorylated by the relevant kinases, and
only then capable of binding 14-3-3 proteins. However, analysis
of Rnd3 phosphorylation status revealed that this is unlikely
because the different Rnd3 CAAX box mutants were still phos-
phorylated to comparable levels as the wild-type Rnd3 (Pro-Q
Diamond, pS210; Figure 4A).
To validate the contribution of Rnd3 farnesylation to 14-3-3
interaction, we used a farnesyltransferase inhibitor (FTI). FTI
treatment led to Rnd3 accumulation in the cytoplasm and
nucleus (Figure S4A), as previously described (Roberts et al.,
2008). FTI treatment prevented wild-type Rnd3 and Rnd3-AllA-
S210/218/240 binding to 14-3-3 proteins (Figure 4B). FTI
treatment only slightly reduced Rnd3 phosphorylation (ProQ
Diamond, pS210; Figure 4B). Increasing the level of Rnd3 phos-
phorylation by coexpression of ROCK11–420 or treatment with
PMA did not induce 14-3-3 interaction in the presence of FTI
(Figure S4B). FTI treatment similarly inhibited Rnd1 and Rnd2
interaction with 14-3-3 (Figure 4C) and morphological changes
(data not shown). These results indicate that Rnd farnesylation
is specifically required for 14-3-3 protein interaction.
Phosphorylation of Ser-240 and Farnesylation of Cys-
241AreBoth Required for Stable Rnd3Binding to 14-3-3
Our data show that, in addition to phosphorylation, C-terminal
farnesylation of Rnd proteins is required for their interaction
with 14-3-3. To further investigate the role of each of these post-(D) Alignment of C-terminal regions of three humanRnd proteins, using Rnd3 prote
with underlined S/T denoting known phosphorylated residues in Rnd3.
(E and F) COS7 cells transfected with the indicated constructs encoding wild-ty
20min. Cell lysates were immunoprecipated with FLAG antibody and stainedwith
Asterisk (*) indicates IgG light chain. See also Figure S2.
Open access under CC translational modifications to the Rnd3/14-3-3 interaction, we
synthesized peptides corresponding to the last C-terminal ten
amino acids of Rnd3 (232–241) that were phosphorylated on
S240 and/or farnesylated at C241 (Table S3). Peptide competi-
tion experiments showed that, of the four peptides tested, the
peptide that was phosphorylated but not farnesylated only
slightly inhibited the interaction between GST-14-3-3b and
Rnd3, whereas the peptide that was both phosphorylated and
farnesylated strongly inhibited the interaction, indicating that far-
nesylation increases peptide binding to 14-3-3b (Figure 5A).
Because the peptides were also biotinylated at the N terminus,
we used a peptide pull-down assay to show that only the phos-
phorylated and farnesylated peptide could efficiently interact
directly with recombinant 14-3-3b (Figure 5B). To further charac-
terize the relative contributions of phosphorylation and farnesy-
lation to binding, the affinity of each peptide for 14-3-3 proteins
was determined by isothermal titration calorimetry. The farnesy-
lated and phosphorylated peptide had an15-fold higher affinity
for 14-3-3z compared to a phosphorylated, but not farnesylated,
peptide (Table 1 and Figure 5C). The other two peptides did not
bind detectably (Figure S5). These results indicate that both
phosphorylation and farnesylation of Rnd3 are required for
optimal binding to 14-3-3 and that the farnesyl group must
directly interact with 14-3-3 proteins to stabilize the interaction.
Recognition of a Phosphorylated and Farnesylated Rnd3
C-Terminal Peptide by 14-3-3
To establish the structural basis for the requirement of both a far-
nesyl and phosphorylation modification for the 14-3-3:Rnd3
complex formation, we determined the 2.3 A˚ crystal structure
of a Rnd3 farnesylated phosphorylated C-terminal peptide
(spanning residues 232 to 241) bound to 14-3-3z (Table S4; Fig-
ure S6). Although the entire 15-carbon farnesyl moiety is not
resolved in the structure, continuous electron density for the first
two 5-carbon isoprenyl units (labeled as Pr1 and Pr2) is clearly
evident extending from the Cys241 thiol and makes contacts
to a hydrophobic patch within 14-3-3 (Pro165, Ile166, Leu216,
Ile217, Leu220, and Leu172) (Figures 6A and 6B). The crystal
structure shows how farnesylation extends the length of the
Rnd3 C terminus able to interact with 14-3-3, despite Rnd3 lack-
ing a consensus 14-3-3-binding motif flanking pSer240 at the C
terminus (Figure 6C). This extension adds a significant hydro-
phobic surface to the interaction by engaging a complementary
groove on 14-3-3 bearing hydrophobic residues. Other Rnd3
peptide contacts, more typical of high-affinity phosphodepend-
ent 14-3-3-binding motifs, include electrostatic interactions
centered on pSer240 of Rnd3 and a basic cluster (Lys49,
Arg56, and Arg127) on 14-3-3 (Figure 6B). Another important
feature is the multiple hydrogen bonds made by main-chain
atoms from Rnd3 with 14-3-3 side chains (Asn173, Asn224,
and Glu180), serving to orient the backbone of the Rnd3 C
terminus.
  in sequence numbering. Sequences are shown in single letter amino acid code,
pe or mutated Rnd1, Rnd2, or Rnd3 were treated with Calyculin A (Cal. A) for
Pro-QDiamond reagent or immunoblotted with antibodies to FLAG and 14-3-3.
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Figure 3. 14-3-3 Binding Inhibits Rnd3 by
Inducing Translocation from the Plasma
Membrane to the Cytosol
(A and B) NIH 3T3 cells were cotransfected with the
indicated constructs. (A) Cell morphology quantifi-
cation. Graph shows pooled results from technical
triplicates in three independent experiments (n = 300
cells/condition/experiment). Conditions with the
same number (1, 2, 3) are not statistically significantly
different from each other. Error bars indicate mean ±
SEM; Table S2 shows statistical analysis between
the conditions. (B) Single confocal images (maximum
intensity z stack projections in merge) showing cell
morphology and FLAG-Rnd3 localization. Arrows:
FLAG-Rnd3-expressing cells (F-actin images) with a
rounded phenotype with protrusions. Arrowheads:
normal phenotype. Scale bar, 20 mm.
(C) The indicated constructs were transfected into
COS7 cells prior to cell lysis and biochemical frac-
tionation. Fractions were immunoblotted with indi-
cated antibodies. ERK1/2 and transferrin receptor
are markers of cytosolic and membrane fractions,
respectively. As controls (bottom panels), cells were
transfected with the Rnd3 nonisoprenylated mutant
S241 or Rnd3WT with staurosporine (stau.), PMA, or
calyculin A (cal. A) treatment. b, 14-3-3b; ROCK1,
myc-ROCK11-420; T, total extracts; N, nuclear frac-
tion; C, cytosolic fraction; M, membrane fraction.
See also Figure S3 and Table S2.
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Figure 4. Rnd Farnesylation Is Required for Interaction with 14-3-3
Proteins
(A–C) The indicated constructs were transfected into COS7 cells. Cell lysates
were immunoprecipitated with FLAG antibody. Endogenous 14-3-3 proteins
bound to FLAG-Rnd3 were detected with 14-3-3 antibody. Membranes were
stained with Pro-Q Diamond reagent or probed with the indicated antibodies.
(B) COS7 cells were treated ± FTI overnight prior to cell lysis. The space in the
gel image marks the position of lanes that were not germane to these results
and were thus removed during figure preparation for clarity. (C) COS7 cells
were treated with calyculin A (Cal. A) for 20 min ± FTI overnight prior to cell
lysis. Asterisk (*) indicates IgG light chain. See also Figure S4.The structure explains the requirement for the Rnd3 farnesyl
group shown by pull-down and calorimetry data. The farnesyl
moiety contributes significant additional hydrophobic contacts,
effectively switching Rnd3 from having a truncated 14-3-3-bind-
ing motif lacking a proper consensus to a high-affinity site. We
notice that the 14-3-3 hydrophobic groove is also used by the
Pseudomonas aeruginosa toxin ExoS (Ottmann et al., 2007).
Both Rnd3 and ExoS peptides lack a proline residue character-
istic of other 14-3-3 motifs that allows a sharp exit from the 14-3-
3 peptide-binding site (Figure 6C). Instead Rnd3 and ExoS can
extend into the 14-3-3 hydrophobic groove. ExoS lacks a phos-Open access under CC phoserine and binds 14-3-3 in an opposite orientation (N to C) to
Rnd3, but makes analogous contacts on 14-3-3 as the Rnd3
farnesyl group (Figure 6D). ExoS has been assigned as a more
specialized mode IV 14-3-3-binding motif, defined by engage-
ment of this 14-3-3 hydrophobic patch (Ottmann et al., 2007).
In fact, Rnd3 does not fit either a canonical phospho-Ser/Thr-
dependent mode I- or mode II-binding motif for 14-3-3, as it
lacks an Arg residue N-terminal to and a Pro residue C-terminal
to pSer240 (Figures S2C and 6C) (Obsil and Obsilova, 2011).
Without the farnesyl group, Rnd3 would resemble a mode III
14-3-3-binding consensus, matching the sequence pS/pT-
X(1-2)-COOH (Figure 6C). Such motifs bind considerably weaker
than mode I or mode II (Obsil and Obsilova, 2011). We therefore
conclude that Rnd proteins possess a hybrid III/IV 14-3-3-bind-
ing motif where the presence of the farnesyl group on the
C-terminal Cys241 permits the engagement of the ‘‘mode IV’’
hydrophobic patch on 14-3-3 but retains elements of a
consensus resembling the mode III motif (Figures 6B and 6C).
Geranylgeranylated Rnd3 and Rap1A Bind to 14-3-3
The unexpected interaction of the Rnd3 farnesyl group with
14-3-3 led us to investigate the number of isoprenyl groups
required for 14-3-3 interaction. We therefore synthesized Rnd3
C-terminal peptides containing between one and four isoprenyl
groups (Table 2). Using biolayer interferometry, we obtained
similar high-affinity values for the farnesylated and phosphory-
lated Rnd3 peptide to those obtained by calorimetry (Table 2).
We also found that the Rnd3 peptide with pS240 and only one
isoprenyl group (C5) had an approximately 10-fold lower affinity
for 14-3-3 compared to Rnd3 peptides with two isoprenyl groups
(geranyl, C10), three (farnesyl, C15) and four (geranylgeranyl,
C20). Interestingly, the affinity gain was mainly achieved by a
5-fold decrease in koff (Table 2). Similarly, Rnd3 peptide pull-
down experiments showed that polyisoprenylated phosphopep-
tides bound most effectively to 14-3-3 (Figure 7A). Together
these results indicate that two isoprenyl groups (observed in
the crystal structure, Figure 6A) are the minimum requirement
for tight 14-3-3 binding, and that the 14-3-3-binding pocket
can accommodate the longer geranylgeranyl group as well as
the farnesyl moiety.
To determine whether other prenylated proteins in addition to
Rnd proteins could interact with 14-3-3 using a hybrid III/IV-
binding motif, we searched protein sequence databases using
a C-terminal consensus motif, [RK]-X-K-[ST]-C-X(3), defined by
key contacts identified in the Rnd3/14-3-3 crystal structure.
The search identified the Rnd proteins as well as the geranylger-
anylated proteins PDE6C, RPGR, and Rap1A (Figure 7B).
Another search was performed using a ‘‘relaxed’’ consensus
motif [RK]-X-[RK]-X(0,1)-[ST]-C-X(3), allowing insertion of an
extra residue next to the phosphorylated Ser/Thr as well as a
less strict requirement for a Lys in the 1/2 position. Among
the candidates, Rap1Bwas selected because it is closely related
to Rap1A (Figure 7B). RhoG was chosen because it has an Arg
residue instead of the 1 Lys that directly binds to Asp223 of
14-3-3 (Figures 7B and 6C). Peptides derived from the C termini
of these candidate proteins were synthesizedwith the physiolog-
ically relevant prenyl modification and tested for their ability to
interact with 14-3-3. Geranylgeranylated and phosphorylatedCell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. 647
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Figure 5. Ser240 Phosphorylation and
Cys241 Farnesylation Are Both Essential
for Rnd3/14-3-3 Interaction
(A) Farnesylated and/or phosphorylated peptides
corresponding to the Rnd3 C terminus (see Table
S3) were used as competitors for GST-14-3-3b
pull-down experiment with lysates from COS7
cells transfected with FLAG-Rnd3. Bound (peptide
competition) and unbound (input) fractions were
immunoblotted with the indicated antibodies. A
PKCε (PKC) peptide corresponding to a high
affinity 14-3-3-binding sequence was used as a
positive control.
(B) Biotinylated peptides were incubated with
recombinant 14-3-3b, followed by immunoblotting
for 14-3-3.
(C) Isothermal titration calorimetry analysis of
14-3-3z binding to Rnd3 peptides. Top: raw data;
bottom: fitted curves.
, no peptide;PF, no modification; +PF, with
phosphorylation; P+F, with farnesylation; +P+F,
with phosphorylation and farnesylation. See also
Figure S5 and Table S3.Rap1A and PDE6C peptides interacted with 14-3-3 with a similar
affinity to the equivalent farnesylated or geranylgeranylated
Rnd3 peptides (Tables 2 and S5). RPGR had an intermediate
affinity, whereas Rap1B and RhoG peptides displayed a lower
affinity for 14-3-3. For RhoG peptide, the low affinity was due
to a decrease in kon (Table S5). This suggests that an Arg adja-
cent to the pSer is poorly tolerated and cannot compensate for
Lys at this position. Similarly, the poor Rap1B-binding affinity
confirms that Lys at1 is crucial to the Lys-pSer/Thr-Cys-prenyl
motif (Figure 7B).
To validate these data, we pursued the interaction with Rap1A
further because its peptide had the highest affinity of those
tested for 14-3-3, and it is a Ras superfamily GTPase known to
be phosphorylated by PKA on the S180 adjacent to the geranyl-
geranylated C181 (Quilliam et al., 1991). Biolayer interferometry
analysis demonstrated that the phosphorylated and geranylger-
anylated peptide displaying an affinity of 25 nM for 14-3-3z,
whereas phosphorylated nongeranylgeranylated Rap1A peptide
had micromolar affinity (Figure 7C). In addition, Rap1A coimmu-
noprecipitated with 14-3-3 proteins (Figure 7D). Taken together,
these results indicate that the established consensus motif was
able to identify new prenyl and pSer-dependent 14-3-3 partners
with a hybrid III/IV-binding motif and suggest that additional648 Cell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc.  Open access under CC BY license.membrane-anchored proteins could
indeed be regulated by 14-3-3.
DISCUSSION
Rnd proteins are atypical G proteins that
are not regulated by the classic GDP/
GTP switchmechanism. Here we demon-
strate they are inhibited by 14-3-3
proteins, which use a novel hybrid III/IV
14-3-3 mode to simultaneously engage
the C-terminal farnesyl group and theadjacent phosphorylated serine residues. In addition to Rnd
proteins, we find that Rap1A binds in a similar manner to 14-
3-3. Here, we report a lipid moiety binding to 14-3-3 and of
Ras superfamily GTPases interacting with 14-3-3. Our results
also indicate that 14-3-3 proteins act on Rnd proteins similar to
the actions of GDIs on other Rho GTPases, by facilitating their
extraction from their site of action in membranes and keeping
them inactive by sequestration in the cytoplasm. In contrast to
GDIs, however, 14-3-3 binding to Rnd proteins requires phos-
phorylation by upstream protein kinase(s), providing a key regu-
latory step in their inactivation.
The translocation of Rnd3 from membranes to the cytosol
following phosphorylation by ROCK1 or PKC was previously
reported (Madigan et al., 2009; Riento et al., 2005). Here we
identify that S210 in Rnd3 is the major PKC phosphorylation
site, which contributes to 14-3-3 binding and hence loss of
membrane localization. In order for PKC activation to induce
Rnd3 translocation (Madigan et al., 2009), S240 must have
been phosphorylated, as this site is essential for 14-3-3
interaction. ROCK and PKC are members of the AGC kinase
family, and most AGC kinases show a preference for phosphor-
ylating Ser/Thr residues downstream of basic residues (Pearce
et al., 2010). It is therefore conceivable that other AGC kinases
Table 1. Effect of Rnd3 Peptide Modifications on 14-3-3 Binding
Rnd3 Peptide Stoichiometry (N) Kd (mM) TDS (kcal/mol) DH (kcal/mol) DG (kcal/mol)
+P+F 0.83 ± 0.014 0.069 ± 0.025 6.843 ± 0.24 2.956 ± 0.06 9.798 ± 0.23
+P-F 0.89 ± 0.017 1.06 ± 0.04 2.469 ± 0.231 5.683 ± 0.204 8.152 ± 0.027
P+Fa - ND no binding - -
P-Fa - ND no binding - -
Thermodynamic parameters for Rnd3 C-terminal peptides and 14-3-3z-binding constants are shown; mean ± SD, n = 3. Titrations of +P+F and +P-F
peptides binding to 14-3-3z were carried out at 25C. ND, not detectable; P, phosphorylation on S240; F, farnesylation; see Table S3 for peptides.
aBinding of P+F and P-F peptides to 14-3-3z was tested at 15C and 25C, where binding was not detected.might phosphorylate Rnd3 and thereby regulate its activity
under different conditions.
14-3-3 dimers classically bind to two pSer/pThr residues
within the context of surrounding consensus amino acid resi-
dues (Obsil and Obsilova, 2011). In Rnd3 none of the three
pSer sites contributing to 14-3-3 binding conforms to the
consensus mode I or mode II motifs. Our data show that the
interaction of the farnesyl moiety with the hydrophobic patch
on 14-3-3 strongly increases the affinity of the weak binding of
a nonfarnesylated peptide with pS240 to the 14-3-3 phos-
phate-binding pocket. Moreover, mutational analysis indicates
that pS240 is absolutely required for 14-3-3 binding, whereas
phosphorylation of S210 and S218 enhances the interaction in
cells. It is therefore likely that one of the 14-3-3 subunits in the
dimer binds first with high affinity to the farnesyl group and
pS240, whereas the other subsequently interacts with either
pS210 or pS218. Such combinatorial high- and low-affinity
asymmetric interactions have been demonstrated for 14-3-3
interaction with the phosphorylated V3 domain of PKCε (Koste-
lecky et al., 2009). Based on our results, the previously observed
cytosolic translocation induced by PKCphosphorylation of Rnd3
(Madigan et al., 2009) can now be seen as providing the addi-
tional 14-3-3 interaction required to complete the extraction
from membranes.
Interestingly, we have found that the other Rnd subfamily
members, Rnd1 and Rnd2, are also phosphorylated in cells
and regulated by 14-3-3 proteins. Like Rnd3, both Rnd1 and
Rnd2 require the Ser adjacent to the Cys of the CAAX box and
farnesylation to interact with 14-3-3, indicating that they use
the hybrid III/IV-binding motif to bind to 14-3-3. Rnd2 has been
reported to be mainly cytosolic in NIH 3T3 fibroblasts, although
it is also on endosomes (Roberts et al., 2008). The relative level
of cytosolic to membrane-bound Rnd proteins is likely to reflect
the proportion of the protein that is phosphorylated, which in turn
depends on the activity of the upstream kinases. In contrast to
Rnd1 and Rnd3, Rnd2 does not induce cell rounding or loss of
stress fibers. This could reflect its interaction with a distinct set
of proteins (Riou et al., 2010). Rnd2 and Rnd3 act at different
stages of cortical neuron migration during development (Pacary
et al., 2011), and thus it would be interesting to know how their
activity is modulated by the 14-3-3 interaction during this
process.
Rnd proteins are part of the Ras superfamily of small
GTPases, most of which are posttranslationally modified at
the C terminus by farnesylation or geranylgeranylation. We
have used a consensus ‘‘hybrid III/IV’’ motif based on theOpen access under CC BRnd3 peptide/14-3-3 crystal structure to identify Ras superfam-
ily GTPases as well as other prenylated proteins that might
interact with 14-3-3. This allowed us to identify Rap1A as a
14-3-3 partner, implying that Rap1A is likely to be inhibited
by phosphorylation and 14-3-3 binding in a similar manner to
Rnd proteins. Consistent with this hypothesis, it has been
reported that PKA-induced phosphorylation on Ser180 of
Rap1A inhibits its interaction with the NADPH oxidase (Bokoch
et al., 1991) and Raf (Hu et al., 1999). Another mechanism for
extracting Ras and Ras-related GTPases from membranes
has been described for PDEd, which interacts with Ras and
Rheb farnesyl groups (Chandra et al., 2012; Ismail et al.,
2011; Nancy et al., 2002). We have found that 14-3-3 interaction
with Rnd proteins induces their translocation from membranes
to the cytosol, but in contrast to RhoGDIs or PDEd, in this
case the process requires Rnd phosphorylation as well as
farnesylation.
Most G proteins cycle between an active GTP-bound and
inactive GDP-bound form. In contrast, Rnd proteins do not
hydrolyse GTP and are constitutively GTP-bound (Riou et al.,
2010). We propose that Rnd proteins are instead regulated
dynamically by phosphorylation and dephosphorylation. Phos-
phorylation of Rnd3 C-terminal sites by ROCK and PKC
leads to 14-3-3 binding, which then extracts Rnd3 from
membranes and prevents it from signaling. ROCKs and most
PKCs localize predominantly on membranes when they are
active, thereby bringing them in close proximity to Rnd3. The
most likely downstream target for Rnd3 on membranes is
p190RhoGAP, which leads to downregulation of RhoA and
hence loss of stress fibers and cell rounding. Notably, Rnd3
bound to p190RhoGAP is not phosphorylated, supporting our
conclusions that Rnd3 is inactivated by phosphorylation and
14-3-3 binding. Conversely, dephosphorylation of Rnd3 by a
phosphatase would induce 14-3-3 dissociation, membrane
binding, and Rnd3 activation.
Importantly, our results provide a paradigm for regulating
prenylated GTP-binding proteins through phosphorylation and
subsequent 14-3-3-mediated extraction from membranes by
interaction with the farnesyl or geranylgeranyl group. Given
that 14-3-3 interaction with Rnd proteins requires the Ser adja-
cent to the farnesylated Cys, it is not possible for 14-3-3 proteins
to bind effectively to this phosphorylated residue without
extracting the protein from membranes. Indeed, phosphoryla-
tion of Rnd proteins and Rap1A in the cluster of basic amino
acids near their C termini is likely to promote membrane extrac-
tion by reducing interaction with acidic phospholipids in theCell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. 649
 Y license.
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Figure 6. Recognition of Phosphorylated
and Farnesylated Rnd3 C-Terminal Peptide
by 14-3-3 Reveals a Hybrid III/IV-Binding
Mode
(A) Structure of the Rnd3 C-terminal farnesylated
phosphopeptide bound to 14-3-3z shown with the
SIGMAA-weighted 2Fo  Fc electron density omit
map (s = 1.0). Electron density is observed for the
first two isoprenyl units (Pr1 and Pr2) extending
from Cys241.
(B) Schematic view of the Rnd3 C-terminal
farnesylated phosphopeptide bound to 14-3-3.
Selected side chains from 14-3-3 making contact
with Rnd3 are shown.
(C) Sequence alignment of representative 14-3-3-
binding motifs indicating how the Rnd family
C-terminal motif is a hybrid III/IV motif with fea-
tures of both a type III and IV motif. Addition of
a farnesyl group effectively extends the length
of Rnd3 similar to the ExoS-binding interaction.
Red ball indicates the phosphoresidue (except
for ExoS which has an alanine). The carboxyl
terminus of Rnd and H+ATPase are shown as
CO2H and the peptide chain direction of 14-3-3
motif sequences is indicated by an N and C
subscript. Note the ExoS peptide is oriented in the
opposite direction to all other 14-3-3 motifs (N-C
rather than C-N).
(D) Superposition of the Rnd3 C-terminal farnesy-
lated phosphopeptide (black sticks) with the
exoenzyme S peptide (ExoS, blue sticks, PDB
code 2O02) and PKCε (salmon sticks, PDB code
2WH0), superposed through their respective 14-3-
3 partners (gray surface). Hydrophobic residues
from 14-3-3 (green sticks and green surface)
contacting Rnd3 isoprenyl units 1 and 2 are
labeled. Note the ExoS peptide is oriented in an
opposing direction (N-C rather than C-N). Atoms
are colored according to standard conventions,
red, oxygen; blue, nitrogen; yellow, sulfur; gray,
carbon; and green, phosphorus. (A) and (D) were
prepared using the graphics program PYMOL
(http://www.pymol.org).
See also Figure S6 and Table S4.membrane. This is similar to the proposed ‘‘farnesyl-electro-
static switch’’ mechanism for reduced plasma membrane inter-
action of K-Ras4B following PKC phosphorylation within its
polybasic C terminus (Ahearn et al., 2012). It will be interesting
to test if other prenylated proteins identified as 14-3-3 interactors
in our peptide screen are also regulated by 14-3-3-dependent
extraction from membranes.650 Cell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc.  Open access under CC BY license.EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
COS7 cells grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% bovine fetal calf
serum and penicillin/streptomycin (Invitrogen)
were electroporated with 5 mg DNA at 250 V and
960 mF using 0.4 cm Gene Pulser Cuvettes (Bio-
Rad) in 250 ml of electroporation buffer (120 mM
KCl, 10 mM K2PO4/KH2PO4 [pH 7.6], 25 mM
HEPES [pH 7.6], 2 mM MgCl2, and 0.5% Ficoll).Cells were analyzed 24 hr after transfection. NIH 3T3 cells grown in DMEM
containing 10% donor bovine serum and penicillin/streptomycin were trans-
fected using FuGENE 6 (Roche) according to the manufacturer’s instructions.
Where indicated, cells were treated for 20 min with 100 nM calyculin A (Alexis);
for 2 hr with 100 nM staurosporine (Calbiochem), 20 mMH-1152 (Calbiochem),
1 mM bisindolylmaleimide I (BIM1, Calbiochem), or 100 nM phorbol-12-myris-
tate-13-acetate (PMA, Cell Signaling Technology); and for 16 hr with 10 mM
L-744,832 farnesyltransferase inhibitor (FTI, Calbiochem).
Table 2. Effect of Rnd3 Prenyl Group Length on 14-3-3 Binding
Rnd3 peptide KD (nM) kon (M
1 s1) koff (s
1) c2 R2
P-F NB N/A N/A N/A N/A
+P-F 1300a N/A N/A N/A N/A
+P+Ipr 556 2.4 3 105 1.3 3 101 0.02 0.99
+P+G 56.5 5.7 3 105 3.2 3 102 0.16 0.99
+P+F 32.4 8.6 3 105 2.8 3 102 0.16 0.99
+P+GG 23.2 8.9 3 105 2.1 3 102 0.08 0.99
The affinities of differently modified C-terminal Rnd3 peptides for 14-3-3z
were determined by biolayer interferometry. Data of a typical experiment
(nR 3) along with statistics of the fit (c2, R2) are listed. See Table S3 for
Rnd3 peptide sequence. P, phosphorylated on S240; Ipr, isoprenylated;
G, geranylated; F, farnesylated; GG: geranylgeranylated; KD, dissociation
constant; kon, association rate constant; koff, dissocation rate constant;
NB, no binding; N/A, not applicable.
aDetermined by steady-state analysis.
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Figure 7. Interaction of Phosphorylated and Prenylated Proteins
with 14-3-3
(A) Biotinylated peptides corresponding to the Rnd3 C terminus modified with
different prenyl groups were incubated with recombinant 14-3-3z, followed by
immunoblotting for 14-3-3.
(B) Alignment of C-terminal sequences of prenylated candidate proteins with
Rnd3 C-terminal sequence. Sequences are shown in single letter amino acid
code; underlined S denotes phosphorylated S240 in Rnd3. The CAAX box
residues are represented in italic.
(C) Binding of 14-3-3z to immobilized biotinylated Rap1A peptides. Biolayer
interferometry was used to assess the binding of a phosphorylated Rap1A
peptide with or without the geranylgeranyl modification. The geranylgerany-
lated peptide has a standard-binding profile. The nonmodified phosphopep-
tide showed little binding, whereas a negative control with no immobilized
peptide gave no response.
(D) Constructs encoding GFP-Rap1A and GFP were transfected into COS7
cells. Endogenous 14-3-3 proteins bound to immunoprecipitated GFP-Rap1A
were detected with 14-3-3 antibody. The membrane was probed with the
indicated antibodies.
See also Table S5.Cell Fractionation
Transfected COS7 cells were treated with pharmacological inhibitors as indi-
cated, then washed in cold PBS. Cells were incubated for 5 min in 900 ml of
cold fractionation buffer (20 mM Tris HCl [pH 8.0], 150 mM NaCl, 10 mM
NaF, 1 mM DTT, 250 mM sucrose) containing EDTA-free protease inhibitor
cocktail (Roche) and phosphatase inhibitor cocktails (set II+IV, Calbiochem).
Cells were scraped into microfuge tubes and lysed by shearing with a dounce
homogenizer. Samples were then centrifuged (4C, 20 min, 900 g). The pellet
(nuclear fraction) was washed twice in fractionation buffer, before addition of
SDS-Urea loading buffer (8 M Urea, 2% SDS, 50 mM Tris HCl [pH 6.8],
0.3% bromophenol blue). The supernatant fraction was centrifuged (4C,
60min, 180,000 g) to separate the cytosol (supernatant) from organelles, cyto-
skeleton and membranes (pellet). Proteins from the cytosol and membrane
pellet fractions were precipitated in 10% trichloroacetic acid (4C, 30 min),
centrifuged (13,000 g, 10 min), and pellets washed in acetone before resus-
pension in SDS-Urea loading buffer. Samples were analyzed by SDS-PAGE
and immunoblotting.
Immunoprecipitation
Transfected COS7 cells were lysed in lysis buffer LB (1% Triton X-100, 20 mM
Tris–HCl [pH 8], 130 mM NaCl, 1 mM dithiothreitol [DTT], 10 mM sodium fluo-
ride, complete EDTA-free protease inhibitor cocktail [Roche], phosphatase in-
hibitor cocktails [set II+IV, Calbiochem]). After centrifugation (13,000 g, 4C,
10 min), soluble proteins were precleared then incubated with either mouse
nonimmune IgG as a control, mouse anti-HA (HA-7) or mouse anti-FLAG
(M2) antibody on agarose beads (Sigma-Aldrich) for 2 hr at 4C. Beads were
washed five times with lysis buffer (containing 260 mMNaCl), then bound pro-
teins were eluted in Laemmli sample buffer (LSB), resolved by SDS–PAGE and
analyzed by immunoblotting.
In Vitro Binding Assay with Phosphatase Treatment and In Vitro
Kinase Assay
FLAG-Rnd3-transfected COS7 cells were lysed in LB buffer without phos-
phatase inhibitors, and Rnd3 proteins immunoprecipitated. The beads
were washed three times in 0.5 M NaCl, followed by two washes with phos-
phatase buffer PB (100 mM NaCl, 50 mM Tris-HCl [pH 7.9], 10 mM MgCl2,
1 mM DTT). Beads in PB buffer were separated equally in two tubes and
incubated ± calf intestinal alkaline phosphatase (CIP, 20 U; New England
Biolabs) at 37C for 60 min. Equal amount of total lysates from COS7 cells
expressing HA-tagged 14-3-3 isoforms were then added to each of the
treated beads (±CIP) for 90 min at 4C for binding. Beads were washed
with LB buffer, bound proteins were eluted in LSB, resolved by SDS–
PAGE and analyzed by immunoblotting.
Kinase assays were carried out on prewashed beads in kinase
buffer (50 mM Tris/HCl [pH 7.5], 10 mM MgCl2, 1 mM DTT, 30 mM ATP,
0.1 mCi/ml [g -32P]ATP) with 7.5 ng of ROCK1 and PKCz kinase domains atOpen access under CC30C for 30 min. Proteins were eluted from beads in LSB, resolved by
SDS/PAGE and protein phosphorylation was analyzed by autoradiography
of dried gels.
Peptide Pull-Down Assay
Biotinylatedpeptides (1 to 10mg; TableS3; ExtendedExperimental Procedures)
were bound to streptavidin-agarose beads (Sigma-Aldrich) for 30 min at 4C
and washed in LB buffer with 0.5% Triton X-100. Recombinant 14-3-3b or z
(2.5mg; seeExtendedExperimental Procedures)was thenaddedand incubated
for 60min at 4C for binding, followedby fivewashes prior to elution frombeads
in LSB, then resolved by SDS–PAGE and analyzed by immunoblotting.
GST-Pull-Down and Peptide Competition Assay
Recombinant GST-14-3-3bwas expressed and purified from E. coli (Extended
Experimental Procedures). FLAG-Rnd3-transfected COS7 cells were lysed in
LB buffer. After removal of insoluble material, precleared cell lysates were
incubated at 4C for 2 hr with the recombinant GST or GST-14-3-3b protein
(5 mg) on glutathione beads (Amersham Biosciences). Beads were washedCell 153, 640–653, April 25, 2013 ª2013 Elsevier Inc. 651  BY license.
with LB buffer before eluting the proteins in LSB. The proteins were resolved by
SDS-PAGE and analyzed by immunoblotting.
For peptide competition experiments (Table S3; Extended Experimental
Procedures), peptides (10 mg/ml) were preincubated for 15 min at 4C with
the GST-14-3-3b prior to the addition of precleared cell lysates.
Isothermal Titration Calorimetry and Biolayer Interferometry
ITCmeasurements were carried out using a VP-ITC200 instrument (GEHealth-
care). The 14-3-3z domain (see Extended Experimental Procedures) was used
at 50–60 mM in ITC buffer (50 mM Tris [pH 7.5]), 100 mM NaCl, 1 mM TCEP).
Rnd3 C-terminal peptides were solubilized in ITC buffer and used at 500–
600 mM. Titrations were carried out at 25C in triplicate. Each titration was
fitted to a simple one-site binding model using the Origin software provided
with the instrument. Titrations with nonbinding peptides were carried out at
15C and 25C.
Biolayer interferometry was carried out using an Octet RED96 instrument
(ForteBio). Biotinylated peptides were immobilized on streptavadin-coated
biosensors (ForteBio) at a concentration of 1 mg/ml in BI buffer (25 mM Tris,
150 mM NaCl, 0.1% Tween-20), for 300 s. The immobilization typically
reached a response level of 2 nm. Association and dissociation curves were
obtained through addition of a dilution series of 14-3-3z (20 to 4,000 mM) for
300 s followed by dissociation in BI buffer for 300 s using the Octet acquisition
software. The binding data were fitted using the Octet analysis software.
Crystallization, Data Collection, and Refinement
A peptide corresponding to residues 232-241 of human Rnd3 with Ser-240
phosphorylated and Cys-241 farnesylated (N-term: DLRKDKAKpSC(S-farne-
syl); Table S3) was synthesized (Extended Experimental Procedures). The
peptide was soluble at 2 mg/ml in buffer A and mixed at a 5-fold molar excess
with 14-3-3z in buffer A. The 14-3-3z:Rnd3 peptide complex was concentrated
to 36 mg/ml and crystallized by sitting drop vapor diffusion (well solution:
0.17 M Sodium Acetate; 0.085 M Tris [pH 8.5]; 25.5% (w/v) PEG4000, 15%
(v/v) glycerol). Crystallization drops were set up using 200 nl of complex with
200 nl of well solution over 100 ml of well solution. The crystals (with a plate
morphology) were flash-frozen in liquid N2, with cryoprotection provided by
the mother liquor.
X-ray diffraction data were collected, on beamline I-24, at the Diamond Light
Source. The data were processed and scaled using D*TREK (Pflugrath, 1999).
The structure was solved using molecular replacement with PHASER (McCoy
et al., 2007) and a 14-3-3 search model derived from the pdb file 2WH0.
Refinement, using data to 2.3 A˚, was undertaken with PHENIX.REFINE
(Afonine et al., 2005) and using torsion angle noncrystallographic symmetry
(NCS) and translation/library/screw (TLS) restraints (each 14-3-3 chain having
three TLS groups and each Rnd3 peptide a single group) with manual
rebuilding using COOT (Emsley and Cowtan, 2004) after each round. Parame-
ters for the Cys-farnesyl link were derived using JLIGAND (Lebedev et al.,
2012), with all other parameters coming from the REFMAC monomer library
(Vagin et al., 2004).
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